Loading market dashboard
Marti Technologies, Inc.
MRTTechnologyAMEXTR
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Marti Is Highly Risky, Financially And Operationally
Marti Technologies, Inc. (MRT) Q1 2026 Earnings Call Transcript
ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced its financial and operational results for the first quarter ended March 31, 2026, delivering strong revenue growth and continued operating leverage across its multi-service mobility platform. Financial and Operational Highlights for First Quarter 2026 Marketplace demand accelerated across the platform: Total trips increased 93% YoY to 16.2 mill.
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti”) (NYSE American: MRT), Türkiye's leading mobility super app, will announce its financial and operational results for the quarter ended March 31, 2026 (“2026 First Quarter Results”) before the U.S. markets open on Thursday, May 21, 2026. Conference Call and Webcast Details Marti's management will host an analyst and investor conference call and live webcast to discuss its 2026 First Quarter Results at 3:30 p.m. Istanbul / 1:30 p.m. Lon.
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim Phase 1/2 clinical data of GSPT1-directed MGD MRT-2359 in combination with an AR inhibitor in mCRPC patients with AR mutations; initiation of Phase 2 study evaluating MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations planned for Q3 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases Preclinical data presented at AACR highlight a novel cyclin E1-directed MGD with superior selectivity and reduced off-target activity compared to CDK2 inhibitors; IND submission anticipated in H2 2026 Strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $671 million, expected to support operations into 2029 BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter ended March 31, 2026. “We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations,” said Markus Warmuth, M.D.
Morguard Real Estate Investment Trust (MRT.UN:CA) Q1 2026 Earnings Call Transcript
ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced a new share repurchase program. The Company's Board of Directors (the “Board”) authorized a new share repurchase program under which the Company may repurchase up to $2.5 million of its outstanding Class A ordinary shares until October 26, 2026 (the “Repurchase Program”). The Repurchase Program replaces the Company's prior share repurchase prog.
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, announced that it has filed its annual report on Form 20-F, including its financial results, for the fiscal year ended December 31, 2025 (the “2025 Annual Report”) with the U.S. Securities and Exchange Commission. The 2025 Annual Report can be accessed under the “Financial Info” section of the Company's investor relations website at https://ir.marti.tech/. I.
Marti Technologies, Inc. (MRT) offers hyper-growth exposure to Turkey's e-hailing and mobility market, combining ride-hailing, delivery, and self-use fleet services. MRT's 2025 revenue grew 110.3% year-over-year, with adjusted EBITDA margin improving from -104% to -31%, signaling early operating leverage and monetization progress. Management guides for 2026 revenue of $70 million and positive adjusted EBITDA, supported by rapid ride growth and SG&A stabilization.
Marti Technologies, Inc. (MRT) Q4 2025 Earnings Call Transcript
ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced its financial and operational results for the full year ended December 31, 2025. Financial and Operational Highlights for the Full Year 2025 Strong Platform Services Growth and Scaling: Continued strong platform momentum, exceeding operational ride-hailing targets throughout the year, with all-time unique ride-hailing riders up 103% YoY and reg.
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti”) (NYSE American: MRT), Türkiye's leading mobility super app, will announce its financial and operational results for the fiscal year ended December 31, 2025 (“2025 Fiscal Year Results”) before the U.S. markets open on Monday, April 13, 2026. Conference Call and Webcast Details Marti's management will host an analyst and investor conference call and live webcast to discuss its 2025 Fiscal Year Results at 3:30 p.m. Istanbul / 1:30 p.m.
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, announced today that as of March 17, 2026, Marti's ride-hailing service has reached 3.80 million riders and 490 thousand registered drivers, exceeding the March 31, 2026 targets of 3.80 million riders and 485 thousand registered drivers. Marti's number of ride-hailing riders grew 101% from March 17, 2025 to March 17, 2026. The number of registered drivers gr.
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window Company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with elevated CVD-risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations Phase 2 study initiation of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations anticipated in Q3 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation by Novartis of multiple Phase 2 studies in immune-mediated diseases $345 million upsized follow-on financing further strengthens balance sheet, supporting operations into 2029 and through multiple anticipated Phase 2 study initiations and clinical data readouts BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2025. “Monte Rosa is now on the cusp of Phase 2 trial initiations for three clinical-stage programs, each targeting expansive opportunities.
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, today announced the launch of the Marti Shareholder Loyalty Program, a new initiative designed to reward long-term retail shareholders while reinforcing Marti's commitment to sustainable growth, stakeholder alignment, and responsible value creation. The Marti Shareholder Loyalty Program provides verified retail shareholders with exclusive benefits directly c.
